Science AI Journal
Medicine · Research topic

Open research questions in Liver Disease Diagnosis and Treatment

489 unresolved questions extracted from the limitations and future-work sections of 1,124 Liver Disease Diagnosis and Treatment papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Investigate the mechanisms underlying the association between LAP-defined steatosis and cardiometabolic risk - Examine the effects of intensive CV risk management on cIMT progression in RA patients with LAP-defined steatosis - Study the relationship between LAP-defined steatosis and other CV risk factors in RA patients

    LAP-defined hepatic steatosis and cardiometabolic risk in rheumatoid arthritis: a post-hoc analysis of the FRANCIS randomized trial · 2026 · DOI

  • The current research gap is the need to understand the relationship between hepatic steatosis and CV risk in RA patients. There is a lack of studies examining the association between LAP-defined steatosis and cIMT in RA patients.

    LAP-defined hepatic steatosis and cardiometabolic risk in rheumatoid arthritis: a post-hoc analysis of the FRANCIS randomized trial · 2026 · DOI

  • Further research is mandatory to define SRP efficacy and safety in patients with MAFLD, - Further research is mandatory to define SRP efficacy and safety in patients with periodontitis

    Efficacy and safety of scaling and root planing for non-alcoholic fatty liver disease · 2026 · DOI

  • The relationship between periodontitis and MAFLD severity is not well understood. There is a need to investigate the efficacy and safety of SRP for MAFLD.

    Efficacy and safety of scaling and root planing for non-alcoholic fatty liver disease · 2026 · DOI

  • The lack of integration of the liver into the cardiovascular-kidney-metabolic syndrome, despite its recognition as a key component of systemic metabolic dysfunction. The need for a comprehensive framework for understanding the relationships between the liver, cardiovascular system, kidney, and metabolic function. The requirement for therapeutic developments that target the liver and its role in the syndrome.

    Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications · 2026 · DOI

  • the study only included individuals from the Korean National Cancer Registry, - the study did not account for other potential risk factors, - the study had a limited follow-up period of 10.5 years, - the study excluded subjects who had been diagnosed with cancer within 1 year of their health checkup

    Differential Cancer Risks and Noninvasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis · 2026 · DOI

  • further studies are needed to investigate the relationship between MASLD and HCC risk, - research should focus on the development of noninvasive markers for cancer risk, - studies should explore the association between MetALD and ALD and other types of cancer

    Differential Cancer Risks and Noninvasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis · 2026 · DOI

  • The study faced the challenge of analyzing a large retrospective cohort of patients with CHB. The study had to address the issue of right-skewed HBV DNA values. The study needed to integrate transcriptomic analyses with clinical findings.

    MAFLD is linked to lower HBV DNA levels in chronic hepatitis B: clinical and transcriptomic insights · 2026 · DOI

  • The impact of MAFLD on HBV replication remains incompletely understood. There is a need to investigate the association between MAFLD and HBV DNA levels.

    MAFLD is linked to lower HBV DNA levels in chronic hepatitis B: clinical and transcriptomic insights · 2026 · DOI

  • The sex- and obesity-specific associations of body composition indices with metabolic dysfunction-associated steatotic liver disease remain incompletely characterized. Traditional obesity indices have limitations in assessing metabolic risk. There is a need to investigate the associations between body composition indices and disease prevalence in a Chinese general population.

    Association between body composition and metabolic dysfunction-associated steatotic liver disease in Chinese general population: a cross-sectional study stratified by sex and obesity status · 2026 · DOI

  • The study faced challenges in identifying MASLD patients with MASH or significant fibrosis using conventional ALT thresholds. The authors had to address the issue of limited liver biopsy data. The study required the development of alternative thresholds and markers for diagnosing MASH and significant fibrosis.

    Identifying MASLD Patients with MASH or Significant Fibrosis: The Role of Lower ALT Thresholds · 2026 · DOI

  • Liver biopsy is limited in clinical practice, particularly among patients with normal ALT, - The study is retrospective and cross-sectional, - The sample size may not be representative of the entire population

    Identifying MASLD Patients with MASH or Significant Fibrosis: The Role of Lower ALT Thresholds · 2026 · DOI

  • Investigating the effects of Semaglutide and CRV431 in other models of MASLD. Examining the potential benefits of combining GLP-1 receptor agonism with other antifibrotic therapies. Studying the mechanisms underlying the divergent biological effects of Semaglutide and CRV431.

    Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model · 2026 · DOI

  • The paper identifies a gap in the treatment of advanced MASLD, where more effective and acute treatments are needed. The current treatments for MASLD, including GLP-1 RAs, have limitations, and the combination of GLP-1 receptor agonism with cyclophilin inhibition may offer a new therapeutic approach.

    Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model · 2026 · DOI

  • Investigate mechanisms driving divergent trajectories - Develop more reliable methods for distinguishing between subtypes - Improve alcohol exposure quantification and integration into risk stratification

    Steatotic liver disease spectrum: From MASLD to MetALD and beyond - Clinical outcomes and precision medicine frontiers · 2026 · DOI

  • The gap lies in the implementation challenges post-nomenclature change. There is a need to understand the mechanisms and genetic modifiers driving divergent trajectories.

    Steatotic liver disease spectrum: From MASLD to MetALD and beyond - Clinical outcomes and precision medicine frontiers · 2026 · DOI

  • The study had to exclude participants with missing data for at least two of the four anthropometric measurements. The study had to account for the limited number of severe fatty liver cases to avoid bias. The study had to adjust for various covariates, including demographic characteristics and lifestyle factors.

    Ultrasound-defined fatty liver and the risk of progression from preclinical to clinical obesity: a prospective cohort study · 2026 · DOI

  • further research is needed to explore the potential sources of heterogeneity, - additional studies are required to evaluate the clinical relevance of metabolic dysfunction in patients with CHB

    Metabolic dysfunction-associated fatty liver and antiviral response in chronic hepatitis B: A systematic review and meta-analysis · 2026 · DOI

  • The importance of identifying non-viral factors that may influence the treatment response and long-term clinical outcomes in patients with CHB. The need to evaluate the associations between MAFLD and antiviral treatment responses and clinical outcomes in patients with CHB.

    Metabolic dysfunction-associated fatty liver and antiviral response in chronic hepatitis B: A systematic review and meta-analysis · 2026 · DOI

  • The paper identifies the challenge of translating effects from earlier non-biopsy studies to histological endpoints. The paper highlights the need for more extensive, well-controlled trials with robust biomarkers to confirm the efficacy of therapeutic approaches. The paper discusses the challenge of managing the complex interactions between genetic predisposition, environmental influences, and metabolic disturbances in MASH and MASLD.

    Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis · 2025 · DOI

  • the study relied on translating effects from earlier non-biopsy studies to histological endpoints, - limitations in existing studies, such as reliance on serum transaminases as outcome markers, - the study s reliance on double-confirmation with non-invasive blood tests and quantitative ultrasound markers, - further confirmation of the drug s impact on clinical outcomes in a larger phase 3 trial is necessary

    Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis · 2025 · DOI

  • MAFLD is a complex disease closely related to metabolic disorders. The development of effective therapeutic drugs for MAFLD is challenging. The study of exosome-like nanovesicles is a relatively new field, and more research is needed to understand their characteristics and biological activity.

    Poria cocos-Derived Exosome-like Nanovesicles Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease by Promoting Mitophagy and Inhibiting NLRP3 Inflammasome Activation · 2025 · DOI

  • Investigate the long-term effects of PCELNs, - Compare PCELNs with existing treatments for MAFLD, - Study the effects of PCELNs on human subjects

    Poria cocos-Derived Exosome-like Nanovesicles Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease by Promoting Mitophagy and Inhibiting NLRP3 Inflammasome Activation · 2025 · DOI

  • The study identifies the challenge of developing effective therapies for liver fibrosis. The authors mention the complexity of the pathophysiological process of liver fibrosis. The study highlights the need for further research on the antifibrotic activity of remogliflozin.

    Protective role of remogliflozin against experimental liver fibrosis by activating AMPK/SIRT1/Nrf2 and suppressing NF-κB pathways · 2025 · DOI

  • There is a lack of understanding of the antifibrotic activity of remogliflozin. The study aims to fill this gap by investigating the preventive activity of remogliflozin against thioacetamide-induced liver fibrosis.

    Protective role of remogliflozin against experimental liver fibrosis by activating AMPK/SIRT1/Nrf2 and suppressing NF-κB pathways · 2025 · DOI

Most-cited papers in Liver Disease Diagnosis and Treatment

Most recent work

Find a gap in your own Liver Disease Diagnosis and Treatment sub-topic

This page shows what the Liver Disease Diagnosis and Treatment literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
489 open questions have been extracted from the limitations and future-work passages of 1,124 Liver Disease Diagnosis and Treatment papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.